Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Update

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Get Free Report) was the recipient of a significant growth in short interest in December. As of December 31st, there was short interest totalling 18,500 shares, a growth of 203.3% from the December 15th total of 6,100 shares. Approximately 0.2% of the shares of the company are short sold. Based on an average daily volume of 10,700 shares, the short-interest ratio is currently 1.7 days.

Armata Pharmaceuticals Price Performance

Shares of Armata Pharmaceuticals stock remained flat at $2.02 on Tuesday. 2,910 shares of the stock traded hands, compared to its average volume of 13,964. Armata Pharmaceuticals has a 1 year low of $1.80 and a 1 year high of $4.48. The company has a market capitalization of $73.08 million, a PE ratio of -1.23 and a beta of 0.78.

Analysts Set New Price Targets

Separately, HC Wainwright restated a "buy" rating and issued a $7.00 price objective on shares of Armata Pharmaceuticals in a research report on Thursday, December 19th.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.